化合物 T23819
| 中文名称 | 化合物 T23819 |
|---|---|
| 中文同义词 | 化合物 T23819;N,N'-[9[[4-(二甲氨基)苯基]氨基]-3,6-吖啶二基]双(1-吡咯烷丙酰胺)三盐酸盐;三盐酸BRACO-19;BRACO19 3HCL |
| 英文名称 | N,N′-(9-(4-(Dimethylamino)phenylamino)acridine-3,6-diyl)bis(3-(pyrrolidin-1-yl)propanamide) trihydrochloride |
| 英文同义词 | N,N′-(9-(4-(Dimethylamino)phenylamino)acridine-3,6-diyl)bis(3-(pyrrolidin-1-yl)propanamide) trihydrochloride;BRACO19 hydrochloride;BRACO19 trihydrochloride;N,N'-[9[[4-(Dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-1-pyrrolidinepropanamide trihydrochloride;BRACO-19 (BRACO19);N,N-[9[[4-(Dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-1-pyrrolidinepropanamide Trihydrochlori;BRACO19 HCl |
| CAS号 | 1177798-88-7 |
| 分子式 | C35H44ClN7O2 |
| 分子量 | 630.23 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1177798-88-7.mol |
| 结构式 |  |
化合物 T23819 性质
| 储存条件 | 2-8°C |
|---|---|
| 溶解度 | H2O：可溶5mg/mL，澄清 |
| 形态 | 粉末 |
| 颜色 | 黄色至棕色 |
| 水溶解性 | H2O: 5mg/mL, clear |
| InChIKey | MJAPNWJRLLDPAB-UHFFFAOYSA-N |
| SMILES | Cl.Cl.Cl.CN(C)c1ccc(Nc2c3ccc(NC(=O)CCN4CCCC4)cc3nc5cc(NC(=O)CCN6CCCC6)ccc25)cc1 |
IC50: telomerase
Braco-19 trihydrochloride, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication.BRACO-19 trihydrochloride (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC 50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC 100 is 5 μM.BRACO-19 trihydrochloride (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses.BRACO-19 trihydrochloride (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells.BRACO-19 trihydrochloride (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner.
Cell Viability Assay
| Cell Line: | HEK 293 cells |
| Concentration: | 20 μM; 40 μM |
| Incubation Time: | 24 hours |
| Result: | Displayed low cytotoxicity and decreased the eGFP fluorescence. |
BRACO-19 trihydrochloride (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts. BRACO-19 trihydrochloride (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors).
| Animal Model: | Established UXF1138LX Xenografts in nude mice |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments |
| Result: | Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-15523A | 化合物 T23819 Braco-19 trihydrochloride | 1177798-88-7 | 5 mg | 1000元 |
| 2026/06/05 | HY-15523A | 化合物 T23819 Braco-19 trihydrochloride | 1177798-88-7 | 10 mM * 1 mLin Water | 1547元 |